Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03: interim results of a randomised, active-controlled, observer-blinded, phase 3 trial

BACKGROUND: GBP510 vaccine contains self-assembling, recombinant nanoparticles displaying SARS-CoV-2 spike receptor-binding domains. We report interim phase 3 immunogenicity results for GBP510 adjuvanted with AS03 (GBP510/AS03) compared with ChAdOx1-S (Vaxzevria, AstraZeneca) in healthy adults aged...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Joon Young, Choi, Won Suk, Heo, Jung Yeon, Kim, Eun Jin, Lee, Jin Soo, Jung, Dong Sik, Kim, Shin-Woo, Park, Kyung-Hwa, Eom, Joong Sik, Jeong, Su Jin, Lee, Jacob, Kwon, Ki Tae, Choi, Hee Jung, Sohn, Jang Wook, Kim, Young Keun, Yoo, Byung Wook, Jang, In-Jin, Capeding, Maria Z., Roman, François, Breuer, Thomas, Wysocki, Piotr, Carter, Lauren, Sahastrabuddhe, Sushant, Song, Manki, D'Cor, Naveena, Kim, Hun, Ryu, Ji Hwa, Lee, Su Jeen, Park, Yong Wook, Cheong, Hee Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498190/
https://www.ncbi.nlm.nih.gov/pubmed/37711219
http://dx.doi.org/10.1016/j.eclinm.2023.102140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498190/
https://www.ncbi.nlm.nih.gov/pubmed/37711219
http://dx.doi.org/10.1016/j.eclinm.2023.102140

Ejemplares similares